Boehringer Ingelheim Korea

Boehringer Ingelheim Korea is the South Korean subsidiary of the global German pharmaceutical giant Boehringer Ingelheim. Established in 1976, the company operates in both human pharmaceuticals and animal health, delivering innovative therapies across South Korea. Its core therapeutic focus areas include cardio-renal-metabolic (CRM) diseases, respiratory diseases, oncology, and immunology. The company's commercial portfolio features blockbuster treatments such as Jardiance (empagliflozin) for type 2 diabetes, heart failure, and chronic kidney disease, and Ofev (nintedanib) for pulmonary fibrosis. Boehringer Ingelheim Korea actively expands its clinical trial footprint and open innovation partnerships within the vibrant South Korean biotechnology ecosystem.